［1］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］OUDKERK M,LIU S,HEUVELMANS MA,et al.Lung cancer LDCT screening and mortality reduction-evidence,pitfalls and future perspectives ［J］.Nat Rev Clin Oncol,2021,18(3):135-151.
［3］WU F,WANG L,ZHOU C.Lung cancer in China:Current and prospect ［J］.Curr Opin Oncol,2021,33(1):40-46.
［4］VINOD SK,HAU E.Radiotherapy treatment for lung cancer:Current status and future directions ［J］.Respirology,2020,25 Suppl 2:61-71.
［5］SIEGEL RL,MILLER KD,WAGLE NS,et al.Cancer statistics,2023 ［J］.CA Cancer J Clin,2023,73(1):17-48.
［6］MU L,LIU L,NIU R,et al.Indoor air pollution and risk of lung cancer among Chinese female non-smokers ［J］.Cancer Causes & Control,2013,24(3):439-450.
［7］BADE BC,DELA CRUZ CS.Lung cancer 2020:epidemiology,etiology,and prevention ［J］.Clin Chest Med,2020,41(1):1-24.
［8］XING DF,XU CD,LIAO XY,et al.Spatial association between outdoor air pollution and lung cancer incidence in China ［J］.BMC Public Health,2019,19(1):1-11.
［9］MAJUMDER D,DEBNATH R,NATH P,et al.Bromelain and olea europaea (L.) leaf extract mediated alleviation of benzo(a)pyrene induced lung cancer through Nrf2 and NFκB pathway ［J］.Environ Sci Pollut Res Int,2021,28(34):47306-47326.
［10］SALEN ML,EL-ASHMAWY NE,ABD EL-FATTAH EE,et al.Immunosuppressive role of benzo［a］pyrene in induction of lung cancer in mice ［J］.Chem Biol Interact,2021,333:109330.
［11］PETIT P,MAITRE A,PERSOONS R,et al.Lung cancer risk assessment for workers exposed to polycyclic aromatic hydrocarbons in various industries ［J］.Environ Int,2019,124:109-120.
［12］KHAN S,ARIF SH,NASEEM I.Interaction of aminophylline with photoilluminated riboflavin leads to ROS mediated macromolecular damage and cell death in benzopyrene induced mice lung carcinoma ［J］.Chem Biol Interact,2019,302:135-142.
［13］RONDINI EA,WALTERS DM,BAUER AK.Vanadium pentoxide induces pulmonary inflammation and tumor promotion in a strain-dependent manner ［J］.Part Fibre Toxicol,2010,7(1):1-13.
［14］SARGENT LM,PORTER DW,STASKA LM,et al.Promotion of lung adenocarcinoma following inhalation exposure to multi-walled carbon nanotubes ［J］.Part Fibre Toxicol,2014,11(1):1-18.
［15］SHIMKIN MB,STONGER GD.Lung tumors in mice:application to carcinogenesis bioassay ［J］.Adv Cancer Res,1975,21:1-58.
［16］DWYER-NIELD L,HICKEY GA,FRIEDMAN M,et al.The second-generation PGI2 analogue treprostinil fails to chemoprevent tumors in a murine lung adenocarcinoma model ［J］.Cancer Prev Res (Phila),2017,10(11):671-679.
［17］ZAKARIA MA,RAJAB NF,CHUA EW,et al.NTCU induced pre-malignant and malignant stages of lung squamous cell carcinoma in mice model ［J］.Sci Rep,2021,11(1):1-10.
［18］TAGO Y,YAMANO S,WEI M,et al.Novel medium-term carcinogenesis model for lung squamous cell carcinoma induced by N-nitroso-tris-chloroethylurea in mice ［J］.Cancer Sci,2013,104(12):1560-1566.
［19］DAY CP,MERLINO G,VAN DYKE T.Preclinical mouse cancer models:a maze of opportunities and challenges ［J］.Cell,2015,163(1):39-53.
［20］LIU Y,LI Y,LIU S,et al.NK cells mediate synergistic antitumor effects of combined inhibiton of HDAC6 and BET in a SCLC preclinical model ［J］.Cancer Res,2018,78(13):3709-3717.
［21］GARRAWAY LA,JANNE PA.Circumventing cancer drug resistance in the era of personalized medicine ［J］.Cancer Discov,2012,2(3):214-226.
［22］HODGKINSON CL,MORROW CJ,LI Y,et al.Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer ［J］.Nat Med,2014,20(8):897-903.
［23］SIMPSON KL,STONEY R,FRESE KK,et al.A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity ［J］.Nat Cancer,2020,1(4):437-451.
［24］WILLIAMSON SC,METCALF RL,TRAPANI F,et al.Vasculogenic mimicry in small cell lung cancer ［J］.Nat Commun,2016,7(1):1-14.
［25］MALY V,MALY O,KOLOSTOVA K,et al.Circulating tumor cells in diagnosis and treatment of lung cancer ［J］.In Vivo,2019,33(4):1027-1037.
［26］RYGAARD J,POVLSEN CO.Heterotransplantation of a human malignant tumour to "Nude" mice ［J］.Acta Pathol Microbiol Scand,1969,77(4):758-760.
［27］ITO R,TAKAHASHI T,KATANO I,et al.Current advances in humanized mouse models ［J］.Cell Mol Immunol,2012,9(3):208-214.
［28］KIM HR,KANG HN,SHIM HS,et al.Co-clinical trials demonstrate predictive biomarkers for dovitinib,an FGFR inhibitor,in lung squamous cell carcinoma ［J］.Ann Oncol,2017,28(6):1250-1259.
［29］OWONIKOKO TK,ZHANG G,KIM HS,et al.Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer ［J］.J Transl Med,2016,14(1):1-14.
［30］BASCHNAGEL AM,KAUSHIK S,DURMAZ A,et al.Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases ［J］.Sci Rep,2021,11(1):1-13.
［31］WANG X,SUN Y,XU Y,et al.Mini-patient-derived xenograft assay based on microfluidic technology promises to be an effective tool for screening individualized chemotherapy regimens for advanced non-small cell lung cancer ［J］.Cell Biol Int,2021,45(9):1887-1896.
［32］MEEHAN TF,CONTE N,GOLDSTEIN T,et al.PDX-MI:Minimal information for patient-derived tumor xenograft models ［J］.Cancer Res,2017,77(21):e62-e66.
［33］EVRARD YA,SRIVASTAVA A,RANDJELOVIC J,et al.Systematic establishment of robustness and standards in patient-derived xenograft experiments and analysis ［J］.Cancer Res,2020,80(11):2286-2297.
［34］ORTMANN J,RAMPASEK L,TAI E,et al.Assessing therapy response in patient-derived xenografts ［J］.Sci Transl Med,2021,13(620):eabf4969.
［35］CONTE N,MASON JC,HALMAGYI C,et al.PDX finder:A portal for patient-derived tumor xenograft model discovery ［J］.Nucleic Acids Res,2019,47(D1):D1073-D1079.
［36］CHEN Y,ZHANG R,WANG L,et al.Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice ［J］.Cancer,2019,125(21): 3738-3748.
［37］ZHANG L,LIU Y,WANG X,et al.The extent of inflammatory infiltration in primary cancer tissues is associated with lymphomagenesis in immunodeficient mice ［J］.Scientific Reports,2015,5(1):1-6.
［38］LIN S,HUANG G,CHENG L,et al.Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy ［J］.MAbs,2018,10(8):1301-1311.
［39］PYO KH,KIM JH,LEE JM,et al.Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models ［J］.Lung Cancer,2019,127:112-121.
［40］WANG M,YAO LC,CHENG M,et al.Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy ［J］.FASEB J,2018,32(3):1537-1549.
［41］LEE J,DYKSTRA B,SPENCER JA,et al.mRNA-mediated glycoengineering ameliorates deficient homing of human stem cell-derived hematopoietic progenitors ［J］.J Clin Invest,2017,127(6):2433-2437.
［42］MERAZ IM,MAJIDI M,MENG F,et al.An improved patient-derived xenograft humanized mouse model for evaluation of lung cancer immune responses ［J］.Cancer Immunology Research,2019,7(8):1267-1279.
［43］HUANG H,ZHU H,XIE Q,et al.Evaluation of (124)I-JS001 for hPD1 immuno-PET imaging using sarcoma cell homografts in humanized mice ［J］.Acta Pharm Sin B,2020,10(7):1321-1330.
［44］SHULTZ LD,BREHM MA,GARCIAIMARTINEZ DJV,et al.Humanized mice for immune system investigation:Progress,promise and challenges ［J］.Nat Rev Immunol,2012,12(11):786-798.
［45］STRIPECKE R,MUNZ C,SCHURINGA JJ,et al.Innovations,challenges,and minimal information for standardization of humanized mice ［J］.EMBO Mol Med,2020,12(7):e8662.
［46］QIAN Y,CHAI S,LIANG Z,et al.KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer ［J］.Mol Cancer,2014,13(1):1-11.
［47］SAITO M,ISHIGAME T,TSUTA K,et al.A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis ［J］.Carcinogenesis,2014,35(11):2452-2456.
［48］HUANG Q,SCHNEEBERGER VE,LUETTEKE N,et al.Preclinical modeling of KIF5B-RET fusion lung adenocarcinoma ［J］.Molecular Cancer Therapeutics,2016,15(10):2521-2529.
［49］ZHONG S,YIN H,LIAO Y,et al.Lung tumor suppressor GPRC5A binds EGFR and restrains its effector signaling ［J］.Cancer Res,2015,75(9):1801-1814.
［50］JING B,WANG T,SUN B,et al.IL6/STAT3 signaling orchestrates premetastatic niche formation and immunosuppressive traits in lung ［J］.Cancer Res,2020,80(4):784-797.
［51］DROSTEN M,BARBACID M.Modeling K-Ras-driven lung adenocarcinoma in mice:preclinical validation of therapeutic targets ［J］.J Mol Med (Berl),2016,94(2):121-135.
［52］GREEN JE,HUDSON T.The promise of genetically engineered mice for cancer prevention studies ［J］.Nat Rev Cancer,2005,5(3):184-198.
［53］COOK N,JODRELL DI,TUVESON DA.Predictive in vivo animal models and translation to clinical trials ［J］.Drug Discov Today,2012,17(5-6):253-260.
［54］BARCK KH,BOU-RESLAN H,RASTOGI U,et al.Quantification of tumor burden in a genetically engineered mouse model of lung cancer by micro-CT and automated analysis ［J］.Transl Oncol,2015,8(2):126-135.
［55］CLOHESSY JG,PANDOLFI PP.Mouse hospital and co-clinical trial project--from bench to bedside ［J］.Nat Rev Clin Oncol,2015,12(8):491-498.